This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: L Brands, The Trade Desk, IDEXX Laboratories, NVIDIA and CrowdStrike
by Zacks Equity Research
The Zacks Analyst Blog Highlights: L Brands, The Trade Desk, IDEXX Laboratories, NVIDIA and CrowdStrike
3 Reasons Why Idexx (IDXX) Is a Great Growth Stock
by Zacks Equity Research
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Top Ranked Growth Stocks to Buy for December 14th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 14th.
Stimulus or No Stimulus, These Large Caps Are Must Buys
by Aniruddha Ganguly
Here we pick five large cap stocks -- LB, TTD, IDXX, NVDA & CRWD -- that are well-poised to grow on solid fundamentals and gradual economic recovery.
KalVista Pharmaceuticals (KALV) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
KalVista Pharmaceuticals (KALV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
3 Growth Stocks to Tap the COVID-Driven Shift in MedTech
by Urmimala Biswas
To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.
Why IDEXX Laboratories (IDXX) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX Laboratories (IDXX).
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
by Zacks Equity Research
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
What Makes Idexx Laboratories (IDXX) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Idexx (IDXX) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Idexx (IDXX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks.com featured highlights include: CRMT, IDEXX, Best Buy and ParkerHannifin
by Zacks Equity Research
Zacks.com featured highlights include: CRMT, IDEXX, Best Buy and ParkerHannifin
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
4 of the Best Stocks That Boast Solid Earnings Growth
by Tirthankar Chakraborty
Americas CarMart (CRMT), Best Buy (BBY), IDEXX Laboratories (IDXX) and PerkinElmer (PKI) currently flaunt striking earnings growth and positive estimate revisions.
Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS
by Zacks Equity Research
Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS
What is a Great Mobility Stock?
by John Blank
You can play pharma...or mobility stocks.
3 Best Buys from the Prospering Medical Instruments Industry
by Urmimala Biswas
Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.
The Zacks Analyst Blog Highlights: Moderna, Lonza Group, BMW, NXP Semiconductors and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Lonza Group, BMW, NXP Semiconductors and IDEXX Laboratories
Vaccine Data Propels Stocks: Global Week Ahead
by John Blank
Moderna said in a Phase 3 trial, which enrolled 30K patients, its vaccine demonstrated 94.5% efficacy. The trial included "many high-risk or elderly" people. Furthermore, their vaccine can be stored a temperatures a commercial freezer can likely supply, easing distribution concerns.
Medtronic (MDT) Integrates InPen With Guardian Connect
by Zacks Equity Research
Medtronic's (MDT) strategic acquisition of Companion Medical strengthens the company's data science and AI capabilities.
Looking for a Growth Stock? 3 Reasons Why Idexx (IDXX) is a Solid Choice
by Zacks Equity Research
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
CVS Health Prescription Volume Solid, Price Cut Woes Stay
by Zacks Equity Research
CVS Health's (CVS) consumer centric digital strategy is even more relevant amid the pandemic.
IDEXX Laboratories' (IDXX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in IDEXX Laboratories (IDXX).
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?